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Background: Non-vitamin K antagonist oral anticoagulants (NOACs) show a favorable balance between
efﬁcacy and safety compared with warfarin for patients with non-valvular atrial ﬁbrillation (NVAF). In
“real-world” practice, however, NOAC adherence and persistence among patients are not clear. The aim
of this study is to evaluate NOAC and warfarin persistence in Japanese patients with NVAF who newly
started these drugs.
Methods: We retrospectively studied 401 patients with NVAF who had newly started NOACs during the
ﬁrst 18 months after our hospital adopted their use (197 dabigatran, 107 rivaroxaban, 102 apixaban) and
200 patients with NVAF who had newly started warfarin during the same period. The endpoint was drug
discontinuation for each drug.
Results: During the follow-up period (up to a maximum of 24 months), 113 (28%) patients who had
newly started NOACs and 33 (17%) patients who had newly started warfarin discontinued the drug. The
persistence rates of patients prescribed NOACs was lower than that of patients prescribed warfarin at 3,
6, and 12 months (85% versus 93%, 79% versus 88%, and 70% versus 82%, respectively). One-tenth of
patients who had newly started NOACs discontinued the drug by their own decision. Drug adverse
events, worsening renal dysfunction, and patient desire were the major causes of NOAC discontinuation.
Conclusions: The rate of persistence of prescribed NOACs was signiﬁcantly lower than that of warfarin in
Japanese patients with NVAF.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is the most clinically prevalent tachyar-
rhythmia [1,2]. AF is a potential risk factor for stroke, and AF-
associated strokes are often severe, resulting in disability or death
[3–6]. Anticoagulant therapy with the vitamin K antagonist warfarin
reduces the risk of AF-related stroke [7]. However, warfarin has been
underused for at-risk patients with AF in clinical practice [8,9].
Additionally, the Anticoagulation and Risk Factors in Atrial Fibrilla-
tion (ATRIA) Study showed that 26.3% of 4188 patients newly starting
warfarin for AF discontinued therapy in the ﬁrst year [10]. In a real-
world setting, adherence to oral anticoagulation therapy is important
for the prevention of stroke in at-risk patients with AF, because
clinical outcomes such as mortality, stroke, and cardiovascular events
are strongly dependent on the quality of anticoagulation and rate of
warfarin discontinuation [11,12].
Recently, several non-vitamin K antagonist oral anticoagu-
lants (NOACs) have been developed. Landmark phase 3 rando-
mized clinical trials (RCTs) compared NOACs with warfarin and
demonstrated that NOACs are at least as safe and effective as
warfarin to prevent stroke/systemic embolisms in patients with
non-valvular AF (NVAF) [13–17]. Current AF guidelines based on
this evidence recommend the risk stratiﬁcation and use of
NOACs [18–21].
The average rates of adherence in RCTs can be remarkably high,
owing to the attention study patients receive and to the selection of
the patients [22]. In “real-world” practice, however, it is not clear
whether the adherence and persistence of patients to NOACs are
better than those to warfarin in patients with NVAF. Moreover, no
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reports have focused on this issue in Japanese patients with NVAF
taking NOACs. The aim of this study was to evaluate NOAC per-
sistence and to compare it with warfarin persistence in Japanese
patients with NVAF who newly started these drugs.
2. Materials and methods
2.1. Subjects
We retrospectively conducted a cohort study of patients with
NVAF who had newly started NOACs during the 18 months after the
adoption of these new drugs in our hospital. All patients were
treated in the Departments of Cardiology and Neurology at Tokyo
Women’s Medical University Hospital. This study included 192
consecutive patients who started dabigatran between March 2011
and September 2012, 107 consecutive patients who started rivar-
oxaban between June 2012 and November 2013, 102 consecutive
patients who started apixaban between April 2013 and September
2014, and as reference, 200 consecutive patients who started
warfarin between March 2011 and September 2012. To identify
patients who were prescribed NOACs and warfarin, we ﬁrst
searched automated prescription databases. Then, we conﬁrmed
each patient’s diagnosis of AF by checking his/her medical records.
We excluded patients with valvular heart disease, concurrent
hyperthyroidism, or hemodialysis, as well as those without risk
factors for stroke. Valvular heart disease was deﬁned as moderate or
severe mitral stenosis and mild rheumatic mitral stenosis according
to angiographic, hemodynamic, or echocardiographic results, or a
history of valvular surgery, including valvular repair or replacement.
This study was approved by the institutional review board of Tokyo
Women’s Medical University (approval number 2887-R).
2.2. Clinical characteristics
Data on patient age, sex, traditional risk factors, underlying
disease, and concomitant medications were obtained from medical
records and laboratory data. Creatinine clearance was calculated
using the Cockcroft–Gault formula [23]. Hypertension was deﬁned
as a systolic blood pressure Z140 mmHg, a diastolic blood pressure
Z90 mmHg, or a history of treatment for hypertension. Diabetes
mellitus previously diagnosed by a physician was deﬁned by treat-
ment with hypoglycemic agents or was indicated by poor glycemic
control (deﬁned as a glycohemoglobin A1cZ6.5%). Coronary artery
disease was deﬁned based on positive stress test results, coronary
angiography demonstrating at least 75% of stenosis, coronary spastic
angina documented by an acetylcholine provocation test, a history of
prior myocardial infarction, or a history of revascularization proce-
dures. Heart failure was deﬁned according to the American College of
Cardiology/American Heart Association criteria [24]; of the patients
included, those who had heart failure were designated as having
stage C (current or prior symptoms of heart failure) or stage D
(refractory heart failure).
The CHADS2 score (congestive heart failure, hypertension,
ageZ75, diabetes, stroke [doubled]) and the CHA2DS2-VASc score
(congestive heart failure/left ventricular dysfunction, hypertension,
ageZ75 [doubled], diabetes, stroke [doubled] – vascular disease,
age 65–74, and sex category [female]) were used to measure
stroke risk.
2.3. Follow-up
Follow-up data were obtained at routine or additional visits at
our institution. The patients were followed until the end of the
follow-up period (24 months after the initiation of each drug, except
for apixaban, where the follow-up period was 22 months; for
dabigatran and warfarin, the follow-up period was until March
2013; for rivaroxaban, this was until May 2014; and for apixaban,
this was until January 2015) or until discontinuation of the drug, loss
to follow-up, or death. Information concerning deceased patients
was obtained from medical records, family members, the patients’
general practitioners, and the hospitals to which they had been
admitted. In patients who started warfarin, we also collected
prothrombin time-international normalized ratio (PT-INR) data.
2.4. Outcomes
Cessation of drugs was deﬁned as discontinuation of the pre-
scribed drug, and physician’s mention of drug cessation on the
medical record. All drug cessations were reviewed from medical
records, and the reasons for cessation were also obtained. Temporary
discontinuation for speciﬁc reasons such as surgery was not con-
sidered as drug cessation. The occurrence of thromboembolic and
bleeding events was validated through the medical records review by
three investigators (M.N., T.S., and T.N.). Thromboembolic events
included fatal or nonfatal ischemic stroke, transient ischemic attack
(TIA), or other systemic embolism. Ischemic stroke was deﬁned as
the sudden onset of a new focal neurological deﬁcit lasting more
than 24 h that could not be explained by other causes. TIA was
diagnosed when the neurological deﬁcit lasted less than 24 h.
Computed tomography or magnetic resonance imaging was per-
formed in all patients. Other systemic embolisms were diagnosed
using computed tomography, angiography, or thrombectomy, and
were based on the absence of underlying atherosclerosis in the
affected artery. Major bleeding events were deﬁned as intracranial
hemorrhage observed by imaging or surgery, intraocular hemorrhage
leading to a substantial loss of vision, or gastrointestinal bleeding or
another severe hemorrhage that was fatal or required endoscopic
hemostasis, surgical intervention, hospital admission, or blood trans-
fusion. For patients who were admitted to other hospitals due to
these events and were not subsequently observed at our hospital, the
information was obtained from those hospitals. A neurologist (T.N.)
also reconﬁrmed the diagnoses of stroke, TIA, and intracranial
hemorrhage in these patients.
2.5. Statistical analysis
Summary data are presented either as the mean and standard
deviation (SD) or as the numbers of patients. Baseline clinical data
were compared between groups with and without depression using
the Student’s t-test and the Mann–Whitney U-test. Categorical
variables were subjected to chi-square analysis. Time in the
therapeutic range (TTR) was calculated using the Rosendaal linear
interpolation method [25], which is a linear interpolation of
consecutive PT-INR values that calculates the percentage of time
that the PT-INR is below, within, or above the target therapeutic
range (1.50–2.49). The rates of events were compared between
individual groups using the chi-square test. The cumulative rates of
persistence for the prescribed drugs were calculated using the
Kaplan–Meier method. Differences in persistence rates were com-
pared using the log rank test. P values o0.05 were considered
signiﬁcant. Data analyses were performed using SPSS statistical
software (version 11.01, SPSS Inc., Chicago, Illinois).
3. Results
3.1. Baseline characteristics
The patients’ baseline characteristics are shown in Table 1. There
were no differences in age or gender between users of NOACs and
warfarin. The proportions of heart failure and diabetes mellitus in
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patients prescribed rivaroxaban were lower than those in patients
prescribed warfarin. However, the proportion of previous stroke/TIA
in patients prescribed dabigatran was higher than that in patients
prescribed warfarin. The distribution of CHADS2 scores was not
different between each NOAC and warfarin, but the proportion of
patients with CHA2DS2-VASc Z4 in patients prescribed dabigatran
was higher than that in patients prescribed warfarin.
3.2. NOAC and warfarin persistence
During the follow-up period, 113 (28%) of 401 patients who had
newly started NOACs discontinued the drug, and 33 (17%) of 200
patients who had newly started warfarin discontinued the drug.
Kaplan–Meier curves for NOAC and warfarin persistence are shown
in Fig. 1. There was a signiﬁcantly higher rate of NOAC discontinua-
tion compared with warfarin discontinuationwithin the ﬁrst year of
treatment. As Fig. 2 shows, patients prescribed warfarin were more
likely than those in the 3 NOAC groups to show drug persistence.
The rate of dabigatran discontinuation was signiﬁcantly higher than
that of warfarin discontinuation within the ﬁrst year of treatment
(hazard ratio 2.19, 95% conﬁdence interval: 1.44–3.34, Po0.01).
3.3. Discontinuation of drugs and cause of cessation
Approximately one-tenth of patients who discontinued the drug
did so of their own accord without consulting a doctor or pharma-
cist (Table 2). Adverse events, including gastrointestinal symptoms
Table 1
Baseline characteristics of the patients.
Dabigatran
(n¼192)
Rivaroxaban
(n¼107)
Apixaban
(n¼102)
Warfarin
(n¼200)
Age, years 7079 70710 70710 68713
Female 50 (26%) 34 (32%) 43 (42%) 65 (33%)
Body weight
(kg)
64711 62714 62714 62713
CCr (ml/min) 72723 67726 66725 71731
Heart failure 34 (18%) 10 (9%)n 20 (20%) 37 (19%)
Hypertension 123 (64%) 67 (63%) 64 (63%) 133(67%)
Diabetes
mellitus
56 (29%) 24 (22%)n 35 (34%) 68 (34%)
Previous stroke/
TIA
91 (47%)nn 28 (26%) 27 (27%) 48 (24%)
Coronary artery
disease
44 (23%) 11 (10%) 15 (15%) 33 (17%)
CHADS2 score
0 28 (15%) 10 (9%) 11 (10%) 32 (16%)
1 35 (18%) 35 (33%) 27 (26%) 45 (23%)
2–6 129 (67%) 62 (58%) 64 (63%) 123(62%)
CHA2DS2-VASc score
0 9 (5%) 5 (5%) 3 (3%) 17 (9%)
1 22 (11%) 13 (12%) 12 (12%) 25 (13%)
2 27 (14%) 16 (15%) 22 (22%) 37 (19%)
3 34 (18%) 34 (32%)n 19 (19%) 40 (20%)
4–9 100 (52%)n 39 (36%) 46 (45%) 81 (41%)
Dose (mg daily) of NOACs
300 mg 15 mg 10 mg
56 (29%) 40 (28%) 66 (65%)
220 mg 10 mg 5 mg
128 (67%) 66 (62%) 36 (35%)
150 mg 5 mg
8(4%) 1 (1%)
The values are expressed as n (%) or mean7SD.
AF, atrial ﬁbrillation; CCr, creatinine clearance; NOACs, non-vitamin K antagonist
oral anticoagulants; TIA, transient ischemic attack.
CHADS2¼cardiac failure, hypertension, age Z75 years, diabetes, previous stroke or
TIA (doubled).
CHA2DS2-VASc¼congestive heart failure/left ventricular dysfunction, hypertension,
age Z75 years (doubled), diabetes, previous stroke/TIA/thromboembolism
(doubled), vascular disease, age 65–74 years, female sex.
n po0.05 compared with warfarin.
nn po0.01 compared with warfarin.
Fig. 1. Kaplan–Meier curves for the persistence of NOACs (n¼401) and warfarin
(n¼200) in non-valvular atrial ﬁbrillation patients. NOAC, non-vitamin K antago-
nist oral anticoagulant.
Fig. 2. Kaplan–Meier curves for the persistence of each NOAC (dabigatran n¼197,
rivaroxaban n¼107, apixaban n¼102) and warfarin (n¼200) in non-valvular atrial
ﬁbrillation patients. NOAC, non-vitamin K antagonist oral anticoagulant.
Table 2
Discontinuation of drugs and causes of cessation.
Event Dabigatran Rivaroxaban Apixaban Warfarin
(n¼192) (n¼107) (n¼102) (n¼200)
Discontinuation 65 (34%) 30 (28%) 18 (18%) 33 (17%)
By the patient’s own decision 5 4 1 3
Causes of cessation
Adverse events 27 (42%) 11 (37%) 9 (50%) 6 (18%)
Gastrointestinal symptoms 8 2 0 1
Bleeding 3 5 1 1
Abnormal laboratory data 8 1 3 3
Other 8 3 5 1
Worsened renal function 6 (9%) 0 0 0
Patient desire 6 (9%) 10 (33%) 2 (11%) 3 (9%)
Poor control of PT-INR 2 (6%)
Maintenance of sinus rhythm 6 (9%) 3 (10%) 3 (17%) 14 (42%)
Other 19 (29%) 6 (20%) 4 (22%) 8 (24%)
PT-INR, prothrombin time-international normalized ratio.
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and bleeding during anticoagulant therapy, were the most common
reason for discontinuing NOACs. Among patients prescribed dabi-
gatran, which is highly excreted by the kidney, worsened renal
function was also an important cause for discontinuation. Patient
desire was the next most common cause. The patients who
discontinued anticoagulation due to maintenance of sinus rhythm
partially included post-AF ablation patients with low risk. Other
causes included cost, number of administrations, two-week limit on
the prescription period, and switching from NOACs to warfarin or
from warfarin to NOACs for surgical/interventional procedures
(Table 2).
3.4. Outcomes
Incidences of thromboembolic and major bleeding events were
not different between patients prescribed NOACs and those pre-
scribed warfarin (Table 3). The mean TTR was 53% during the
initiation and maintenance phases of warfarin therapy. Two
patients with dabigatran experienced ischemic stroke/TIA after
the discontinuation of the drug by their own decision.
Antithrombotic treatment after the discontinuation of drugs is
shown in Table 4. Of the patients who discontinued NOACs, half
received warfarin and one-ﬁfth received a NOAC, mostly another
NOAC. One-fourth of the patients who discontinued warfarin
received NOACs. However, one-ﬁfth of patients who discontinued
NOACs and three-fourths of patients who discontinued warfarin
did not receive any subsequent antithrombotic therapy.
4. Discussion
Our study in patients with NVAF who had newly started NOACs or
warfarin revealed the following ﬁndings: (1) patients prescribed
NOACs had a signiﬁcantly lower drug persistence rate within one
year after the start of the drug than did patients prescribed warfarin;
(2) one-fourth of patients who had newly started NOACs discon-
tinued the drug, and one-tenth of these patients discontinued it by
their own decision without consulting a doctor or pharmacist; (3)
adverse events, worsening renal dysfunction, and patient desires
were the major causes of NOAC discontinuation; (4) incidences of
thromboembolism and major bleeding were not different for NOACs
and warfarin; (5) half of the patients who discontinued NOACs
received warfarin after the discontinuation, but one-ﬁfth of patients
did not receive any subsequent antithrombotic drugs.
4.1. NOAC persistence
In clinical practice, we use NOACs for several patients with NVAF,
who are quite different from the patients selected in RCTs. Drug
persistence is important for the success of anticoagulant therapy. It
is possible that non-adherence to or discontinuation of NOACs will
inﬂuence clinical outcome in these patients. The subanalysis of
Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared
With Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation (ROCKET-AF) showed that the risk of
stroke or systemic embolism was similar with rivaroxaban or
warfarin in patients with AF who temporarily or permanently
discontinued anticoagulation [26]. A recent national cohort of
5376 patients with NVAF who started on dabigatran at all Veterans
Affairs hospitals in the US showed that lower adherence was
associated with increased risk for combined all-cause mortality
and stroke [27]. The propensity-matched analysis of that cohort
study also showed that the persistence rate of patients prescribed
dabigatran was higher than that of patients prescribed warfarin at
6, 9, and 12 months, analyzed with a 60-day permissible medication
gap (71.8% versus 53.3%, 66.9% versus 44.0%, 63.3% versus 38.8%,
respectively) [28]. The differences in the medical care systems, e.g.,
the number of regular meetings with a cardiologist for monitoring
of PT-INR and dose adjustment of warfarin, between Japan and the
US might partially inﬂuence the difference in warfarin persistence
between that US cohort and ours. However, this factor might not
inﬂuence dabigatran persistence, which does not require laboratory
monitoring, and the discontinuation of dabigatran in our study was
not particularly low. Although we can check the adherence to
warfarin use by monitoring PT-INR, we cannot assess the adherence
of NOACs, which do not require laboratory monitoring. In our study,
two patients who had discontinued dabigatran by their own
decision experienced ischemic stroke/TIA. This issue will arise as a
new problem in the NOAC era.
4.2. Cause of cessation
In our study, the time to NOAC discontinuation was relatively
shorter (several months) than the time to warfarin discontinuation.
In most cases, discontinuation was because of the adverse events of
the treatment, although these were not severe, or patient desire. In
anticoagulation therapy, minor bleeding is commonly observed but
does not lead to severe or serious major bleeding [29]. However,
patients, especially Japanese patients, dislike experiencing side
effects from drugs. Moreover, patient preference is an important
factor in adherence to anticoagulation treatment. The 2014 Amer-
ican Heart Association/American Stroke Association guideline
recommended that the selection of an antithrombotic agent should
be individualized on the basis of cost, tolerability, and patient
preference, as well as risk factors [30].
4.3. Differences among NOACs
To interpret our results, the drug approval time of each NOAC
should be considered. Dabigatran was ﬁrst approved for use as a
NOAC in Japan in January 2011, prior to its approval in Europe. In
August 2011, the Japanese Ministry of Health, Labour and Welfare
issued a safety advisory to warn of the potential for serious adverse
events with dabigatran; this safety advisory was subsequent to the
death of ﬁve patients who were taking this drug, all of whom were
elderly, and four of whom were suspected of having severe renal
Table 3
Thromboembolic and major bleeding events.
Event Dabigatran Rivaroxaban Apixaban Warfarin
(n¼192) (n¼107) (n¼102) (n¼200)
Thromboembolism
Ischemic stroke 2 2 2 2
TIA 1 0 0 0
Systemic embolism 0 0 0 0
Major bleeding
Intracranial hemorrhage 0 0 1 2
Gastrointestinal bleeding 1 3 0 2
TIA, transient ischemic attack.
Table 4
Antithrombotic treatment after discontinuation of each NOAC and warfarin.
Treatment Dabigatran Rivaroxaban Apixaban Warfarin
(n¼65) (n¼30) (n¼18) (n¼33)
Warfarin 39 (60%) 14 (47%) 8 (44%) 0
NOACs 11 (17%) 8 (27%) 3 (17%) 8 (24%)
Antiplatelet 3 (5%) 2 (7%) 1 (6%) 0
Other antithrombotic therapy 0 0 0 1 (3%)
None 11 (17%) 6 (20%) 6 (33%) 24 (72%)
NOACs, non-vitamin K antagonist oral anticoagulants.
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impairment [31]. Therefore, physicians in Japan were advised to
carefully monitor for signs of anemia and bleeding, and were also
advised to perform renal function tests before and during the
administration of NOACs. These experiences were good opportunities
to allow Japanese physicians to comprehend the pharmacokinetics of
NOACs, particularly their hepatic metabolism, renal excretion, and
drug-drug interactions. Thereafter, many physicians began to pay
attention to the indications and patient selection for NOACs, and
treatment management has been good for the last 4 years. In fact,
there were no differences in the incidences of thromboembolic and
major bleeding events between NOACs and warfarin in our study.
Therefore, the discontinuation rates of rivaroxaban and apixaban
(approved in January and December 2012, respectively) might be
lower than that of dabigatran.
4.4. Antithrombotic treatment after drug discontinuation
In our study, one-fourth of patients who discontinued NOACs
and three-fourths of patients who discontinued warfarin did not
continue with antithrombotic therapy after the discontinuation of
the drug. Although the majority of these patients might have a low
risk of stroke, physicians should not prescribe anticoagulants if they
might have to discontinue anticoagulation therapy. Recent guide-
lines recommend NOACs for patients with low risk [18–21,30].
Physicians should cautiously consider the indications for antic-
oagulant therapy.
4.5. Adherence to NOAC treatment
Several patient-related factors, patient psychology and behavior,
the medication, disease, healthcare system, medical practitioner,
and patient–physician relationship affect adherence to medication
[32,33]. We also need to recognize barriers to adherence. There is
no single approach to ensure patient adherence, and any attempts
to improve adherence must involve the patient in the decision-
making process [32]. Based on our results, the following issues will
be required to improve adherence of NOACs. Before physicians ﬁrst
prescribe a NOAC, they should give patients detailed information
regarding adverse events of the drug that often occur within several
months. Physicians should explain the risk of discontinuation and
the necessity of consulting physicians and pharmacists if the patient
is concerned about discontinuing the drug. Physicians should select
the correct drug based on patient preference as well as cost and risk
of stroke. Patient education and follow-up systems with pharma-
cists at community-dispensing pharmacies in collaboration with
physicians are needed to improve the adherence and management
of anticoagulant therapy in patients with AF.
4.6. Limitations
There are some limitations to this study. First, the study was a
retrospective observational study, and the number of subjects was
small. Additionally, treatment selection bias existed. Second, this
was a single-center cohort study. The clinical characteristics of our
patients might not reﬂect those of average patients with NVAF in
Japan because our institution is a university hospital. Third, we
could not detect all minor events.
5. Conclusions
There was a signiﬁcantly higher rate of discontinuation within
one year after the start of using NOACs compared with warfarin. To
improve adherence to NOACs, further educational and manage-
ment systems for patients with AF will be required.
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